Real patient being treated with DUPIXENT.
Individual results may vary.

Patient Identification

Appropriate patients may
benefit from seeing a
dermatologist or allergist

The latest American Academy of Dermatology treatment guidelines for the management of
moderate-to-severe atopic dermatitis in appropriate adults include a strong recommendation for
the use of systemic therapies, such as DUPIXENT¹

Consider partnering with a specialist for your patients aged 6+ months if they:

Have given ≥1 topical Rx therapy an adequate trial but are still uncontrolled^1-3
Feel that their itch is not well controlled^2,4
Have ≥10% of their body covered with lesions and/or lesions that may involve
problem areas, such as the face, hands, and feet¹

Paulo, at 14 years old being treated for his moderate-to-severe atopic dermatitis (eczema)

Ask yourself 2 simple
questions to assess your
patients aged 6+ months with

moderate-to-severe atopic
dermatitis uncontrolled with
topical Rx therapy

1 2

DU they still itch?

If they have given ≥1 topical Rx therapy an adequate trial but are still uncontrolled^1-3
If they feel that their itch is not well controlled^2,4

1 2

DU they still itch?

Assessing topical Rx therapy and the severity and impact of itch

According to an expert panel of the International Eczema Council, pruritus
may be assessed
using a numerical rating scale (NRS)^2,a

Pruritus NRS assesses average itch intensity over the previous 24 hours by
asking patients a single question⁵:
- “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being ‘worst itch imaginable,’ how would you rate your itch overall (on average)
  during the previous 24 hours?”

^aIn DUPIXENT pivotal trials in adults, baseline weekly averaged
Peak Pruritus NRS score was ≥3 per inclusion criteria.⁴

1 2

DU they still have burdensome lesions?

If the extent and severity of their lesions are
moderate-to-severe^1,3

Lesions from atopic dermatitis (eczema) on arm

1 2

DU they still have burdensome lesions?

Assessing the severity and impact of lesions

Body surface area involvement is one method of assessing disease severity^2,6,a
- ≥10% body surface area involvement is indicative of moderate-to-severe disease^3,6
Even if disease extent is isolated to a particular area (eg, just the hands or face), the impact on the patient may be severe^2,6

^aIn clinical trials of DUPIXENT in uncontrolled moderate-to-severe atopic dermatitis,
patients had baseline body surface area involvement of ≥10% per inclusion criteria.³

Are your patients du for A CHANGE?

Ask yourself 2 simple questions to assess your patients aged 6+ months with moderate-to-severe atopic dermatitis uncontrolled with topical Rx therapy:

DU they still itch?

DOWNLOAD DUPIXENT PATIENT
IDENTIFICATION BROCHURE

DU they still have
burdensome lesions?

DOWNLOAD DUPIXENT PATIENT
IDENTIFICATION BROCHURE Find a Specialist

Patient Identification

Appropriate patients may benefit from seeing a dermatologist or allergist

Are your patients du for A CHANGE?

Appropriate patients may
benefit from seeing a
dermatologist or allergist